Clinical Hematology Series

Multiple Myeloma

The plasma-cell clone — from the M-spike on electrophoresis to the CRAB criteria and the diagnostic triad.

Interactive edition·14 scenes·English·2026
01 · The presentation

A 60-year-old with fatigue

No past history — but the labs tell a whole story at once.

TestValueInterpretation
Hemoglobin10.6 g/dLAnemia
Creatinine1.8 mg/dLRenal insufficiency
Calcium11.2 mg/dLHypercalcemia
Total protein11 g/dLHigh (albumin low at 3.1)
The clue

Serum electrophoresis shows a monoclonal IgA paraprotein — a massive tumour burden hiding behind vague fatigue.

02 · Cell of origin

The plasma cell

The terminal B-cell — the body’s antibody factory, normally 3–5% of marrow, secreting a diverse (polyclonal) mix of immunoglobulins.

Normal · polyclonal

Many different plasma cells make many different antibodies to fight infection.

Malignant · monoclonal

One clone replicates without limit, secreting a single identical immunoglobulin — the paraprotein / M-protein.

03 · Detecting the clone

The M-spike on electrophoresis

Serum proteins separate by charge into bands — albumin to gamma. A monoclonal protein piles up as a tall, narrow spike in the gamma region. Toggle the tracing.

Albuminα1α2βγ
M-spike Albuminα1α2βγ

The spike measures the physical quantity of monoclonal protein — identified by its heavy chain (usually IgG or IgA; IgM suggests Waldenström’s).

04 · The spectrum

From MGUS to symptomatic myeloma

The same clone, escalating. What separates “observe” from “treat” is end-organ damage. Step through the staircase.

MGUS

  • M-spike < 3 g/dL
  • < 10% marrow plasma cells
  • Asymptomatic

Manage: observe.

Smoldering myeloma

  • M-spike ≥ 3 g/dL or ≥ 10% plasma cells
  • Still asymptomatic

Manage: observe.

Multiple myeloma

  • M-spike ≥ 3 g/dL or ≥ 10% plasma cells
  • + symptoms (CRAB)

Manage: treat.

05 · Symptomatic disease

The CRAB criteria

Symptomatic myeloma is defined by end-organ damage — four pillars that explain the whole clinical picture.

C · Calcium

Hypercalcemia — leached from destroyed bone.

R · Renal

Renal insufficiency — cast nephropathy.

A · Anemia

Marrow infiltration + low EPO.

B · Bone

Lytic lesions, fractures.

06 · Bone & calcium

Punched-out lytic lesions

Myeloma tips bone remodelling — up osteoclast (eating), down osteoblast (building).

Consequences

  • Diffuse osteopenia
  • Lytic “punched-out” lesions
  • Pathological fractures
  • Hypercalcemia

The imaging

Lateral skull X-ray — multiple punched-out defects.

07 · Renal & blood

Cast nephropathy & rouleaux

Renal · cast nephropathy

Light chains bind Tamm–Horsfall protein in the tubules, forming insoluble casts that obstruct flow. Worsened by hypercalcemia, hyperviscosity, NSAIDs.

Anemia & infection

Normocytic anemia from marrow infiltration + low EPO. Immunodeficiency because the clonal antibody is useless and normal immunoglobulins are suppressed.

rouleaux
08 · Neurologic

Cord compression & neuropathy

Spinal cord compression

From paraspinal masses or vertebral collapse — a medical emergency.

Peripheral neuropathy

Direct nerve damage by monoclonal protein, or a chemotherapy side effect.

09 · Look-alike

Differential: Waldenström’s

Multiple myelomaWaldenström’s
IgG or IgAIgM (large pentamer)
Lytic bone lesionsHyperviscosity syndrome
Organomegaly (spleen / liver)
No lytic bone lesions

Hyperviscosity engorges retinal veins — the “sausage-link” fundus.

10 · Confirming

The diagnostic triad

Symptomatic myeloma needs all three.

1 · Monoclonal protein

M-spike > 3 g/dL (or urinary Bence-Jones).

2 · Marrow clones

> 10% CD138⁺ plasma cells on biopsy.

3 · End-organ damage

CRAB features present.

The patient’s verdict

M-spike 60 g/L ✓ · anemia + renal + hypercalcemia ✓ → symptomatic multiple myeloma, requiring treatment.

11 · Summary

Epidemiology & takeaway

Who

Median age 65–70; slight male predominance.

How common

1% of all malignancies; 10% of hematologic cancers.

Why

Usually unknown; links to radiation, benzene, chronic antigen stimulation.

“Recognise the journey from silent MGUS to the toxic end-organ damage of symptomatic myeloma.”

Clinical Hematology Series

End of lecture.

← All lectures